Biotech Values

[poorgradstudent]

Trastuzumab elicit adcc that's why none of the her2 tki came close.

Right, except that toxin loaded trastuzumab appears to be more efficacious. And if ADCC type mechanisms were at play and dominant, they would work independent of changes in intracellular signaling... unfortunately, that's not the case. We get Her2+ cancers that do not respond to trastuzumab, which is inconsistent with ADCC.

If the target is expressed specifically on tumor target then therapeutic index allows efficacy without toxicity.

A true panacea. If only there were more than a handful of tumour specific targets. None of the ones you've pointed out are tumour specific.